ReviewAntibiotics (Basel, Switzerland)2022
Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Secondary Prophylaxis of Recurrent Clostridioides Difficile Infections During Systemic Antibiotics With Vancomycin: A Randomized Controlled Trial
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin in Patients Treated With Systemic Antibiotic Therapy in a Community Hospital
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence ofBMJ open · 2023Trial
- Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence ofJAC-antimicrobial resistance · 2026Article
- Outcomes of Implementing a Multidimensional Antimicrobial Stewardship Program in a Medical Ward in a Third-Level University Hospital in Northern Italy.Antibiotics (Basel, Switzerland) · 2025Article
- Clinical management ofEClinicalMedicine · 2025Article
- Navigating recurrentAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- A systematic literature review and bayesian meta-analysis of oral vancomycin primary prophylaxis forAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Use of primary oral vancomycin prophylaxis to stem an outbreak ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Therapeutics involved in managing initial and recurrentWorld journal of gastrointestinal pharmacology and therapeutics · 2024Review
- Review
- TreatingACG case reports journal · 2024Article
- Use of electronic health record data to identify hospital-associatedmedRxiv : the preprint server for health sciences · 2024Article
- The management ofMedicine and pharmacy reports · 2024Review
- Microbiome-Related and Infection Control Approaches to Primary and Secondary Prevention ofMicroorganisms · 2023Review
- Strategies to preventInfection control and hospital epidemiology · 2023Article
- Controversies in the Prevention and Treatment ofMicroorganisms · 2023Review
- Comparison of the Risk of RecurrentOpen forum infectious diseases · 2022Article
- Editorial for the Special Issue: "Current and Novel Antimicrobial Strategies for Bacterial and Fungal Infections by Resistant Organisms".Antibiotics (Basel, Switzerland) · 2022Article
- Primary Prophylaxis for Clostridioides difficile Infection in Lung Transplant Recipients: A Retrospective Study.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsA systematic review with meta-analysis and trial sequential analysis (TSA) of studies assessing the efficacy and the safety of OVP to prevent primary CDI and rCDI in persons undergoing SAT was carried out. PubMed and EMBASE were searched until 30 September 2021. The protocol was pre-registered on PROSPERO (CRD42019145543).
resultsEleven studies met the inclusion criteria, only one being a randomized controlled trial (RCT). Overall, 929 subjects received OVP and 2011 represented the comparator group (no active prophylaxis). OVP exerted a strong protective effect for CDI occurrence: odds ratio 0.14, 95% confidence interval 0.04-0.38. Moderate heterogeneity was observed: I
conclusionsOVP appears to be an efficacious option for prevention of CDI in high-risk subjects undergoing SAT. Nevertheless, additional data from RCTs are needed to establish OVP as good clinical practice and define optimal dosage and duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.